Abbott Tops Q2 Forecasts, Announces New Georgia Facility

Abbott Laboratories reported strong Q2 2025 results, posting adjusted earnings per share of $1.26 and revenue of $11.14 billion, marking a 7.4% increase year-over-year. The company's medical devices division, particularly its continuous glucose monitors, outperformed expectations amid increased diabetes awareness and expanded insurance coverage. Abbott reaffirmed its full-year adjusted EPS guidance at $5.15. The company announced plans to build a new manufacturing facility in Georgia to support its cardiovascular business, supplementing ongoing projects in Illinois and Texas. Abbott reduced its debt from $14.7 billion to $13.3 billion over the past year, maintaining a robust balance sheet with significant cash reserves. While outpacing the S&P 500 this year, investors are advised to monitor future earnings estimate revisions and the company's liability levels.